Wikisage, the free encyclopedia of the second generation, is digital heritage
Amifampridine: Difference between revisions
Jump to navigation
Jump to search
(Created page with "Amifampridine phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submi...") |
m (→Links) |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
Amifampridine | Amifampridine | ||
phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submission for the treatment of congenital myasthenic syndromes and Lambert Eaton myasthenic syndrome (LEMS <ref>https://www.neurologylive.com/clinical-focus/amifampridine-phosphate-shows-success-in-myasthenia-gravis-trial</ref>)<ref>https://www.drugs.com/news/firdapse-amifampridine-approved-rare-autoimmune-disorder-78751.html</ref> | phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submission for the treatment of congenital myasthenic syndromes and Lambert Eaton myasthenic syndrome (LEMS <ref>https://www.neurologylive.com/clinical-focus/amifampridine-phosphate-shows-success-in-myasthenia-gravis-trial</ref>)<ref>https://www.drugs.com/news/firdapse-amifampridine-approved-rare-autoimmune-disorder-78751.html</ref> | ||
==ATC== | |||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | |||
|colspan=2| <center> | |||
<gallery>File:3,4-diaminopyridine-3D-balls.png</gallery> | |||
: [[wikipedia:amifampridine|Amifampridine]] | |||
<ref>[http://www.whocc.no/atc_ddd_index/?code=N07XX05 N07XX05]</ref></center> | |||
|} | |||
==Links== | ==Links== | ||
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder | https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder | ||
[https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trial-snapshot-firdapse?utm_campaign=FIRDAPSE%3A%20New%20Drug%20Trials%20Snapshot%20Posted&utm_medium=email&utm_source=Eloqua&elqTrackId=c2f2cdb9b5df4474865ad177537e17cd&elq=b0824506823d49a8915422ef2620ec8a&elqaid=6329&elqat=1&elqCampaignId=5158 Drug Trial Snapshot: Firdapse] | [https://www.fda.gov/drugs/resources-information-approved-drugs/drug-trial-snapshot-firdapse?utm_campaign=FIRDAPSE%3A%20New%20Drug%20Trials%20Snapshot%20Posted&utm_medium=email&utm_source=Eloqua&elqTrackId=c2f2cdb9b5df4474865ad177537e17cd&elq=b0824506823d49a8915422ef2620ec8a&elqaid=6329&elqat=1&elqCampaignId=5158 Drug Trial Snapshot: Firdapse] | ||
{{refs}} | |||
{{Wikidata| | |||
{{Wikidata|Q411707}} | |||
Latest revision as of 01:15, 7 May 2019
Amifampridine phosphate was granted an Orphan Drug designation by the FDA for MG in September 2016, shortly after receiving a Refusal to File letter from the FDA for its submission for the treatment of congenital myasthenic syndromes and Lambert Eaton myasthenic syndrome (LEMS [1])[2]
ATC
Links
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-lambert-eaton-myasthenic-syndrome-rare-autoimmune-disorder Drug Trial Snapshot: Firdapse
| References: |
